The cholesterol-lowering drug is part of a suite of medicines that also includes MariTide and that Amgen Chief Medical Officer Paul Burton hopes will make the company the “undisputed leader in the ...
Amgen (NASDAQ:AMGN) today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha ® ...
Amgen has joined the wave of major drugmakers setting up direct-to-consumer programs amid President Donald Trump’s call for more DTC options to lower U.S. drug prices. The "AmgenNow" program, launched ...
Amgen on Tuesday reported quarterly financial results that beat Wall Street expectations, and raised its full-year outlook, ...
Amgen (NASDAQ:AMGN) said on Monday that it has launched its cholesterol medication, Repatha, directly to consumers in the U.S. at a reduced cash price. This move comes as part of a broader response ...
Amgen Inc. reported a robust third quarter 2025, with revenues rising to US$9.56 billion and net income increasing to US$3.22 ...
Amgen reported stronger-than-expected quarterly financial results, raising its full-year forecast. The biotech company's 12% ...
(RTTNews) - Amgen Inc. (AMGN) on Thursday announced positive results form the Phase 3 VESALIUS-CV study of Repatha in adults with high cardiovascular risk without prior heart attack or stroke. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback